DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of “Moderate Buy” from Analysts

DexCom, Inc. (NASDAQ:DXCM – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $132.75.

A number of brokerages recently weighed in on DXCM. SVB Leerink lowered their price objective on shares of DexCom from $141.25 to $125.00 in a research report on Friday, April 29th. StockNews.com began coverage on shares of DexCom in a research report on Thursday, March 31st. They set a “hold” rating for the company. Morgan Stanley lowered their price objective on shares of DexCom to $90.75 and set an “equal weight” rating for the company in a research report on Monday, June 13th. BTIG Research lowered their price objective on shares of DexCom from $135.00 to $105.00 and set a “buy” rating for the company in a research report on Friday, June 24th. Finally, Raymond James decreased their target price on shares of DexCom from $134.50 to $121.50 in a research report on Friday, April 29th.

Shares of DexCom stock opened at $77.63 on Tuesday. The firm has a market cap of $30.47 billion, a PE ratio of 150.01, a price-to-earnings-growth ratio of 3.38 and a beta of 1.03. The firm’s 50-day simple moving average is $88.47 and its 200-day simple moving average is $105.72. The company has a debt-to-equity ratio of 0.90, a quick ratio of 4.79 and a current ratio of 5.27. DexCom has a 1 year low of $66.89 and a 1 year high of $164.86.

DexCom (NASDAQ:DXCM – Get Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical device company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.04). DexCom had a net margin of 8.23% and a return on equity of 12.42%. The business had revenue of $628.80 million for the quarter, compared to the consensus estimate of $623.97 million. During the same period in the prior year, the company earned $0.08 EPS. DexCom’s quarterly revenue was up 24.5% on a year-over-year basis. On average, equities analysts predict that DexCom will post 0.74 earnings per share for the current year.

In related news, EVP Chad Patterson sold 777 shares of the stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $342.77, for a total transaction of $266,332.29. Following the completion of the sale, the executive vice president now directly owns 13,675 shares of the company’s stock, valued at $4,687,379.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Steven Robert Pacelli sold 250 shares of the stock in a transaction that occurred on Monday, April 25th. The shares were sold at an average price of $439.94, for a total transaction of $109,985.00. Following the sale, the insider now directly owns 35,425 shares of the company’s stock, valued at $15,584,874.50. The disclosure for this sale can be found here. Insiders sold 3,653 shares of company stock valued at $1,090,922 over the last quarter. Insiders own 0.41% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Riverview Trust Co acquired a new stake in DexCom during the first quarter valued at approximately $25,000. Rise Advisors LLC purchased a new stake in shares of DexCom in the 4th quarter valued at approximately $26,000. Equitec Proprietary Markets LLC purchased a new stake in shares of DexCom in the 4th quarter valued at approximately $29,000. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of DexCom in the 4th quarter valued at approximately $37,000. Finally, American National Bank purchased a new stake in shares of DexCom in the 4th quarter valued at approximately $37,000. 93.26% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

See Also